Watchlist Price Alert

Wave Life Sciences Ltd. (WVE)

NASDAQ: WVE · Real-Time Price · USD

6.63

0.09 (1.38%)

At close: May 09, 2025, 3:59 PM

6.73

1.39%

After-hours: May 09, 2025, 04:15 PM EDT

1.38% (1D)

Bid	6.3
Market Cap	1.02B
Revenue (ttm)	108.3M
Net Income (ttm)	-97.01M
EPS (ttm)	-0.7
PE Ratio (ttm)	-9.48
Forward PE	-6.65
Analyst	Buy

Ask	6.76
Volume	1,260,947
Avg. Volume (20D)	1,438,639
Open	6.53
Previous Close	6.54
Day's Range	6.41 - 6.70
52-Week Range	4.25 - 16.74
Beta	-0.92

About WVE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol WVE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for WVE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Wave Life Sciences has released their quartely earnings on May 8, 2025:

Revenue of $9.18M misses estimates by $2.1M, with -26.82% YoY decline.

EPS of -0.29 misses estimates by -0.04, with -20.83% YoY decline.

Why Price Moved

3 days ago

-17.08%

Shares of vaccine and gene therapy stocks are trad... Unlock content with Pro Subscription

1 week ago

+7.47%

Wave Life Sciences shares are trading higher after Cantor Fitzgerald initiated coverage with an Overweight rating and $10 price target.

News

18 hours ago · seekingalpha.com

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - Pre...

1 day ago · zacks.com

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.

1 week ago · zacks.com

Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

1 month ago · seekingalpha.com

Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531

Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved i...

1 month ago · zacks.com

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near ter...

1 month ago · benzinga.com

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Wave Life Sciences Ltd. WVE released data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon-skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who...

2 months ago · seekingalpha.com

Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Kate Rausch - VP, IR & Corporate Affairs Paul Bolno - President & CEO Erik Ingelsso...